Q-omics provides the consensus-scored NPM1P51 profile across patient tissues and cancer cell-line models. NPM1P51 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, NPM1P51 is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, NPM1P51 RNA expression shows 6,469 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, BRCA, and STAD as cancer lineages where NPM1P51 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPM1P51 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPM1P51 survival associations across molecular data types. NPM1P51 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPM1P51 RNA expression–survival associations across cancer types. High NPM1P51 expression shows unfavorable associations in KICH, MESO, STAD, KIRP and LUSC, but favorable associations in UCS. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KICH as the clearest survival context for NPM1P51 RNA expression.
This table summarizes NPM1P51 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for NPM1P51. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPM1P51 shows lower tumor expression in BRCA, PAAD and UCEC and higher tumor expression in HNSC, LUAD and COAD. The BRCA box plot shows higher NPM1P51 RNA expression in normal versus tumor tissue (log2 FC = −0.027, t-test p = .022).
This table shows molecular features associated with NPM1P51 in patient tissues and cancer cell lines. In patient samples, NPM1P51 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
